Wall Street brokerages expect Flexion Therapeutics, Inc. (NASDAQ:FLXN) to report earnings of ($1.09) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Flexion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.19) and the highest estimate coming in at ($0.99). Flexion Therapeutics posted earnings of ($0.78) per share in the same quarter last year, which indicates a negative year over year growth rate of 39.7%. The company is scheduled to announce its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Flexion Therapeutics will report full year earnings of ($3.84) per share for the current financial year, with EPS estimates ranging from ($3.95) to ($3.73). For the next financial year, analysts forecast that the firm will report earnings of ($4.06) per share, with EPS estimates ranging from ($4.62) to ($3.71). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Flexion Therapeutics.

Several equities research analysts have recently issued reports on the company. Needham & Company LLC raised their price target on Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $37.00 price target (up from $35.00) on shares of Flexion Therapeutics in a research report on Monday, October 9th. Wells Fargo & Company set a $39.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a research report on Friday, October 6th. Janney Montgomery Scott raised their price target on Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a research report on Tuesday, October 10th. Finally, Laidlaw reaffirmed a “buy” rating and issued a $38.00 price target (up from $35.00) on shares of Flexion Therapeutics in a research report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $98.33.

Shares of Flexion Therapeutics (NASDAQ:FLXN) traded down $0.93 during trading hours on Friday, hitting $22.55. The stock had a trading volume of 1,149,900 shares, compared to its average volume of 829,215. Flexion Therapeutics has a 12 month low of $15.96 and a 12 month high of $32.25. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93.

In other Flexion Therapeutics news, insider Michael D. Clayman purchased 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was purchased at an average price of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the purchase, the insider now directly owns 35,395 shares in the company, valued at $835,322. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Yamo Deniz purchased 1,375 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were acquired at an average price of $25.40 per share, with a total value of $34,925.00. Following the purchase, the insider now owns 5,000 shares of the company’s stock, valued at $127,000. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 10,375 shares of company stock valued at $249,575. Corporate insiders own 15.98% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Fiduciary Trust Co. bought a new position in Flexion Therapeutics during the second quarter worth about $101,000. IFP Advisors Inc lifted its stake in Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the period. Advisor Group Inc. lifted its stake in Flexion Therapeutics by 205.9% during the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares during the period. SG Americas Securities LLC bought a new position in shares of Flexion Therapeutics in the third quarter valued at approximately $135,000. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Flexion Therapeutics in the third quarter valued at approximately $235,000. Hedge funds and other institutional investors own 69.17% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Flexion Therapeutics, Inc. (FLXN) Expected to Announce Earnings of -$1.09 Per Share” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/15/flexion-therapeutics-inc-flxn-expected-to-announce-earnings-of-1-09-per-share.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.